<DOC>
	<DOCNO>NCT00137826</DOCNO>
	<brief_summary>The purpose study determine whether combination investigational drug Avastin Tarceva effective patient mesothelioma previously treat chemotherapy .</brief_summary>
	<brief_title>Bevacizumab ( Avastin ) Erlotinib ( Tarceva ) Previously Treated Mesothelioma</brief_title>
	<detailed_description>Each cycle study treatment last 21 day . The patient take erlotinib mouth daily . On day 1 every cycle , patient receive bevacizumab intravenously 30-90 minute time period . CT scan ( ) , MRI ( ) and/or x-ray ( ) cancer site perform every 6 week ( 2 cycle ) assess extent response treatment . Bloodwork perform first dose erlotinib bevacizumab Cycle 1 , Cycle 2 , Cycle 3 , end treatment . At completion treatment physical exam , vital sign , blood test , urine test standard radiologic testing perform . The duration study depend upon patient ' mesothelioma respond treatment well well patient tolerates medication .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Mesothelioma previously treat least one chemotherapy regimen 18 year age old Must least able walk capable take care oneself although unable carry work activity Four week since last major surgery Four week since last radiation therapy Three week since last chemotherapy Life expectancy 12 week Blood test show kidney , liver bone marrow work adequately Able comply study and/or followup procedure Prior exposure Tarceva ( OSI774 , erlotinib ) , trastuzumab , ZD1839 C225 Receiving anticoagulation medication low dose Coumadin Clinically significant heart disease uncontrolled hypertension , previous heart attack within past 12 month , uneven heartbeat , etc . History central nervous system disease seizures control standard medical therapy , brain metastasis history stroke Major surgery within 28 day screen Daily treatment aspirin antiinflammatory medication Pregnant lactating ( pertain woman ) Serious nonhealing wound , ulcer bone fracture Difficulty swallow A disease disorder interfere ability digest absorb food History cough 1/4 teaspoon blood A medical condition could make unsafe patient participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Mesothelioma</keyword>
	<keyword>Avastin</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Tarceva</keyword>
	<keyword>OSI-774</keyword>
	<keyword>Erlotinib</keyword>
</DOC>